AQR Capital Management
OTLK icon

AQR Capital Management’s Outlook Therapeutics OTLK Stock Holding History

AQR Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-96,979
Closed -$155K – 3550
2025
Q2 		$155K Buy
96,979
+12,308
+15% +$19.6K ﹤0.01% 3109
2025
Q1 		$103K Buy
84,671
+25,351
+43% +$44.4K ﹤0.01% 3008
2024
Q4 		$112K Buy
+59,320
New +$244K ﹤0.01% 2756
2024
Q3 		– Sell
-10,164
Closed -$75K – 2849
2024
Q2 		$75K Buy
+10,164
New +$81.6K ﹤0.01% 2516
2022
Q3 		– Sell
-2,602
Closed -$53K – 2283
2022
Q2 		$53K Sell
2,602
-266
-9% -$7.65K ﹤0.01% 2132
2022
Q1 		$102K Sell
2,868
-650
-18% -$20.3K ﹤0.01% 2135
2021
Q4 		$96K Buy
3,518
+66
+2% +$2.35K ﹤0.01% 2155
2021
Q3 		$150K Buy
3,452
+1,652
+92% +$79.7K ﹤0.01% 2174
2021
Q2 		$90K Buy
+1,800
New +$83.5K ﹤0.01% 2192

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's OTLK Position: Q3 2025 in Review

AQR Capital Management sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 96,979 shares — an estimated $155K sold.

AQR Capital Management first reported a position in OTLK in Q2 2021 and held it in 9 quarters. The position peaked at $155K in Q2 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • AQR Capital Management reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 96,979 Outlook Therapeutics shares in Q3 2025, an estimated $155K.
  • AQR Capital Management first reported a position in Outlook Therapeutics in Q2 2021 and held it in 9 quarters.
  • AQR Capital Management's Outlook Therapeutics position peaked at $155K in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.